FDA Approves Roche's Ocrevus ZUNOVO for Relapsing and Progressive Multiple Sclerosis
核心洞察
The FDA has approved Ocrevus ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for both relapsing multiple sclerosis (搜索) (RMS (搜索)) and primary progressive multiple sclerosis (PPMS (搜索)).
Ocrevus ZUNOVO is administered via a roughly 10-minute subcutaneous injection twice a year by a healthcare professional.
The approval is based on the Phase III OCARINA II trial, demonstrating similar efficacy and safety to the IV formulation of Ocrevus.
The U.S. Food and Drug Administration (FDA) has approved Roche's Ocrevus ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (搜索) (RMS (搜索)) and primary progressive multiple sclerosis (PPMS (搜索)). This approval provides a new administration option for Ocrevus, already a well-established therapy for MS.
Ocrevus ZUNOVO is the first and only twice-yearly subcutaneous injection, administered by a healthcare professional in approximately 10 minutes, approved for both RMS (搜索) and PPMS (搜索). Multiple sclerosis (搜索) is a chronic autoimmune disease where the immune system attacks the central nervous system, leading to inflammation and nerve damage.
The FDA's decision was supported by data from the Phase III OCARINA II trial. The study demonstrated that subcutaneous administration of Ocrevus ZUNOVO resulted in blood levels of ocrelizumab comparable to those achieved with the intravenous (IV) formulation of Ocrevus. The safety and efficacy profiles were also consistent between the two formulations in patients with RMS (搜索) and PPMS (搜索).
OCARINA II Trial Details
The Phase III OCARINA II trial evaluated the pharmacokinetics, safety, and efficacy of Ocrevus ZUNOVO compared to Ocrevus IV. The trial met its primary endpoint, showing no clinically significant difference in ocrelizumab blood levels between the subcutaneous and intravenous routes of administration. The safety profile of Ocrevus ZUNOVO was similar to that of Ocrevus IV, with the exception of injection-site reactions, which were more frequently reported with the subcutaneous formulation, especially during the first injection.
Clinical Significance
"OCREVUS ZUNOVO gives patients and providers another option for receiving OCREVUS, building on a decade of robust safety and efficacy data for OCREVUS in multiple sclerosis (搜索)," said Levi Garraway, Roche's chief medical officer and head of Global Product Development. "This approval may offer greater flexibility for healthcare providers and people living with multiple sclerosis, based on their individual treatment needs."
Ocrevus and Ocrevus ZUNOVO are the only therapies approved for both RMS (搜索) and PPMS (搜索), addressing a significant unmet need in MS treatment. The availability of a subcutaneous formulation offers a more convenient administration option for patients, potentially improving adherence and quality of life.